SpyGlass Pharma, Inc.
SGP- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001778922
In the last 90 days, SpyGlass Pharma, Inc. insiders filed 1 open-market purchase and 0 sales; 69 institutions reported holding it in 13F filings for Q3 2026, worth $687.8M in total; no superinvestor holds it.
Holders of 5% or more of SGP
Holders whose latest Schedule 13D or 13G filing reports 5% or more of SpyGlass Pharma, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 13D | 24.10%8.02M shares | New | Feb 17, 20261 filing | Feb 17, 2026 | SEC |
| New Enterprise Associates 17, L.P. | 13D | 22.20%7.39M shares | New | Feb 13, 20261 filing | Feb 13, 2026 | SEC |
| Vensana Capital I GP, LLC | 13D/A | 8.90%2.99M shares | −1.00 ppfrom 9.90% | Feb 10, 20262 filings | Nov 18, 2026 | SEC |
| Sands Capital Life Sciences Pulse Fund III (DE), L.P. | 13G | 7.80%2.50M shares | New | Feb 13, 20261 filing | Feb 13, 2026 | SEC |
| Gilde Healthcare Holding B.V. | 13D | 6.57%2.19M shares | New | Feb 13, 20261 filing | Feb 13, 2026 | SEC |
| Samsara BioCapital, L.P. | 13G | 6.30%2.11M shares | New | Feb 17, 20261 filing | Feb 17, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
7 Schedule 13D and 13G filings on SpyGlass Pharma, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Nov 18, 20264:47 PM ET | Vensana Capital I GP, LLCand 3 others | 13D/A | 8.90%2.99M shares | −1.00 ppfrom 9.90% | Nov 16, 2026 | SEC |
| Feb 17, 20267:23 PM ET | Samsara BioCapital, L.P.and 4 others | 13G | 6.30%2.11M shares | New | Feb 9, 2026 | SEC |
| Feb 17, 20267:21 PM ET | Ra Capital Management, L.P.and 4 others | 13D | 24.10%8.02M shares | New | Feb 9, 2026 | SEC |
| Feb 13, 20266:21 PM ET | New Enterprise Associates 17, L.P.and 14 others | 13D | 22.20%7.39M shares | New | Feb 9, 2026 | SEC |
| Feb 13, 20264:05 PM ET | Gilde Healthcare Holding B.V.and 4 others | 13D | 6.57%2.19M shares | New | Feb 9, 2026 | SEC |
| Feb 13, 202611:36 AM ET | Sands Capital Life Sciences Pulse Fund III (DE), L.P.and 3 others | 13G | 7.80%2.50M shares | New | Feb 6, 2026 | SEC |
| Feb 10, 20266:29 PM ET | Vensana Capital I GP, LLCand 3 others | 13D | 9.90%3.31M shares | New | Feb 9, 2026 | SEC |
Form 144: proposed insider sales
1 notice from officers, directors and other affiliates planning to sell SpyGlass Pharma, Inc. shares, newest first.
| Filed (ET) | Seller | Shares to sell | Market value | Planned sale | Broker | Filing |
|---|---|---|---|---|---|---|
| Nov 18, 20264:40 PM ET | Samsara BioCapital, L.P.Shareholder | 37.2K | $1.17M | Nov 18, 2026 | Merrill Lynch | SEC |